Bioadaptives, Inc. (OTC Pink: BDPT) is engaged within the manufacturing and distribution of natural plant and algal-based health and wellness products for humans and animals. The company’s products primarily focus on pain relief, anti-viral, and immune system defense. Shares of the health and wellness company are skyrocketing 220% through early trading on Thursday, March 23, 2023. Over the past thirty days, Bioadaptives has seen average daily volume of 3.71 million shares. However, volume of 186.1 million shares or dollar volume of around $297,760, has already exchanged hands through early trading.
Shares of Bioadaptives are surging after the company announced it has signed a letter of intent with World Wellness, LLC to develop a comprehensive weight management system. The new system will also incorporate the patented Fit Your Outfit (FYO) app, which leverages artificial intelligence to provide a specific body composition measurement with a single photo taken from the user’s smartphone. The FYO app uses a proprietary technology that involved pixel sizing and counting method to produce real dimension silhouettes. The app is protected by U.S. and E.U. patents. The two companies will seek to develop and distribute new health products aimed at weight management, health & wellness and fitness.
Dr. Edward Jacobs, CEO of BioAdaptives, Inc.: “We are very pleased to be working with Dr. David Allen in this new collaboration. Dr. Allen is considered one of the leading wellness educators and researchers of unique proprietary products in the nutrition industry and digital health marketplace. His company has more than 30 years of experience developing and marketing wellness products in North America, Europe, and Asia. We are excited to participate in this global body composition analyzer market and weight loss app market projected to grow to US$1.4 billion in 2027 and to US$2.6 billion by 2030 respectively.”
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/